Yacoub M. Irshaid, MD, PhD, ABCP

- 1. Follicle-stimulating hormone (FSH).
- 2. Luteinizing hormone (LH).
- 3. Human chorionic gonadotropin (hCG).
- 4. Human menopausal gonadotropins (hMG).

## **Gonadotropins Available for Use**

- 1. Urofollitropin (uFSH): extracted from the urine of postmenopausal women.
- 2. Recombinant FSH (rFSH), follitropin.
- 3. Recombinant human LH (rLH), or Lutropin.
- Choriogonadotropin alfa is a recombinant form of hCG (rhCG), which is a combination of FSH and LH.

#### **Therapeutic Uses:**

- 1. Induction of ovulation: needs progesterone support of the luteal phase.
- 2. Male infertility: for hypogonadal men.

#### **Adverse effects:**

- **1. Ovarian hyper-stimulation syndrome:**
- a) Ovarian enlargement, ascitis, hydrothorax, hypovolemia and sometimes shock.
- b) Hemoperitoneum (from a ruptured ovarian cyst).
- c) Fever and arterial thromboembolism can occur.

- 2. Multiple pregnancies (15-20% vs 1%).
- 3. Headache, depression, edema.
- 4. Production of antibodies against hCG.
- 5. Gynecomastia in males.
- 6. Possible association with ovarian cancer.

### Gonadotropin-Releasing Hormone (GnRH) & Its Analogs

- It is secreted by neurons in the hypothalamus.
- Pulsatile GnRH secretion stimulates the gonadotrophs to produce and release FSH and LH.
- Sustained, nonpulsatile administration of GnRH (or its analogs) inhibits the release of FSH & LH by the pituitary in both women and men → hypogonadism.

- Gonadorelin is an acetate salt of synthetic human GnRH.
- Synthetic analogs include: Goserelin, Leuprolide.
- Duration of clinical use varies from few days to years, therefore, preparations have been developed with a range of duration of action from several hours to months.

 Lower pulse frequencies favor FSH secretion, whereas higher pulse frequencies favor LH secretion.

#### Pharmacologic use:

 Pulsatile IV administration of gonadorelin every 1-4 hours stimulates FSH and LH secretion.

- 2. Continuous administration of gonadorelin or its analogs produces a biphasic response:
- A. During the first 7-10 days, an agonist effect occurs that results in increased concentration of gonadal hormones in males and females – called a flare.

- B. After that, the continued presence of GnRH results in inhibitory action leading to decreased concentrations of gonadotropins and gonadal steroids.
- The inhibitory action is due to receptor downregulation and changes in the signaling pathway.

#### **Therapeutic Uses:**

- A. Stimulation:
- 1. Female and Male infertility: Less commonly used, and less convenient method than gonadotropins.
- 2. As an "LH responsiveness test" to diagnose the cause of delayed puberty.

- **B.** Suppression of gonadotropin production:
- 1. Controlled ovarian hyperstimulation: When multiple mature oocytes are produced in the course of assisted reproduction to suppress endogenous LH surge that could prematurely trigger ovulation.

2. Endometriosis (ectopic estrogen-sensitive tissue): The pain of endometriosis is reduced by abolishing exposure to the cyclical changes in the concentration of estrogen and progesterone which are part of the menstrual cycle.

- **3.** Uterine leiomyomata (fibroids): Estrogensensitive fibrous growths.
- 4. Central (pituitary or hypothalamic) precocious puberty (onset of secondary sex characteristics before 8 years in girls and 9 years in boys).

#### **Adverse effects:**

- 1. Headache, light-headedness, nausea and flushing.
- 2. Local swelling at injections site.
- 3. Hypersensitivity reactions: bronchospasm and anaphylaxis.
- 4. The syndrome of menopause in women.
- 5. Ovarian cysts.

- 6. Sudden pituitary apoplexy: Abrupt hemorrhage or infarction of the pituitary gland within a pituitary adenoma, leading to abrupt onset of severe headache, neck stiffness, visual disturbances, and oculomotor palsies.
- 7. Reduced bone density and osteoporosis.

- **Ganirelix, Cetrorelix** (Synthetic decapeptides):
- •They inhibit FSH and LH secretion in a dosedependent manner.
- **Therapeutic uses:**
- **1.Prevention of the LH surge during controlled ovarian hyperstimulation.**

- An advantage over continuous treatment with GnRH agonists is immediate action, and shorter duration of administration.
- Their use can be delayed until day 6–8 of the in vitro fertilization cycle.

#### On the other hand:

- 1. Adherence to treatment regimen is more critical because effect reverses quickly after discontinuation.
- 2. They produce more complete suppression of gonadotropin secretion.

- 3. Suppression of LH may inhibit ovarian steroidogenesis to an extent that impairs follicular development when FSH is used during the follicular phase of IVF cycle.
- 4. Lower rate of pregnancy in IVF cycles compared with those using GnRH agonists.

B. Treatment of advanced prostate cancer: Degarelix reduces concentrations of gonadotropins and androgens more rapidly than GnRH agonists and avoids the testosterone surge seen with GnRH agonist therapy.

#### **Adverse effects:**

- 1. Nausea and headache are the most common.
- 2. During the treatment of men with prostate cancer, degarelix may cause injection-site reactions and may increase liver enzymes.
- 3. Signs and symptoms of androgen deprivation, including hot flushes and weight gain.

# Prolactin

- 198 aa peptide, similar in structure to growth hormone.
- Principal hormone responsible for lactation.
- Hyperprolactinemia → amenorrhea, galactorrhea and infertility in women; AND loss of libido and infertility in men.
- The hypogonadism and infertility associated with hyperprolactinemia is due to inhibition of GnRH release.

# Prolactin

- The prolactin-inhibiting hormone is dopamine.
- Dopamine agonists are used to treat hyperprolactinemia.
- Adenomas that secrete excess prolactin retain sensitivity to dopamine.

**Dopamine agonists (D<sub>2</sub> receptor):** 

- 1. Ergot derivatives: Bromocriptine, cabergoline, pergolide.
- 2. Nonergot derivatives: Quinagolide.
- Pharmacodynamics:
- 1. Suppress prolactin release effectively in patients with hyperprolactinemia.
- 2. Also suppress GH release in acromegaly.
- 3. Improve motor function in Parkinsonism. <sup>26</sup>

#### **Therapeutic uses:**

- 1. Hyperprolactinemia:
- Shrink pituitary prolactin-secreting tumors.
- Lower circulating prolactin levels.
- Restore ovulation in ~ 70% of women with microadenomas and ~ 30% of those with macroadenomas.
- 3. Acromegaly.
- 4. 4. Parkinsonism.

#### **Adverse effects:**

- 1. Nausea, vomiting, headache, fatigue and lightheadedness.
- 2. Orthostatic hypotension.
- 3. Psychiatric manifestations.
- 4. Erythromelalgia (paroxysmal throbbing and burning pain in the skin).

- 5. Ergots → cold-induced peripheral digital vasospasm.
- 6. Pulmonary infiltrates with chronic high dose therapy.
- 7. Stroke or coronary thrombosis in postpartum women taking bromocriptine to suppress postpartum lactation.